IL95120A - Preparation of sustained release pharmaceutical compositions comprising peptide salts, in the form of microparticles - Google Patents

Preparation of sustained release pharmaceutical compositions comprising peptide salts, in the form of microparticles

Info

Publication number: IL95120A
Authority: IL; Israel
Prior art keywords: trp; cys; phe; microparticles; thr
Prior art date: 1989-07-28

Application number

IL9512090A

Other languages

English (en)

Other versions

IL95120A0 (en

Original Assignee

Debiopharm Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-07-28

Filing date

1990-07-18

Publication date

1994-10-07

1990-07-18 Application filed by Debiopharm Sa filed Critical Debiopharm Sa

1991-06-10 Publication of IL95120A0 publication Critical patent/IL95120A0/xx

1994-10-07 Publication of IL95120A publication Critical patent/IL95120A/en

Links

239000011859 microparticle Substances 0.000 title claims abstract description 29
239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 9
108090000765 processed proteins & peptides Proteins 0.000 title claims description 17
238000002360 preparation method Methods 0.000 title claims description 7
150000003839 salts Chemical class 0.000 title description 11
238000013268 sustained release Methods 0.000 title description 2
239000012730 sustained-release form Substances 0.000 title description 2
238000000034 method Methods 0.000 claims abstract description 26
239000000203 mixture Substances 0.000 claims abstract description 22
239000000725 suspension Substances 0.000 claims abstract description 4
229920001577 copolymer Polymers 0.000 claims description 25
239000013543 active substance Substances 0.000 claims description 16
238000001125 extrusion Methods 0.000 claims description 14
WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims description 13
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical class OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
239000000126 substance Substances 0.000 claims description 10
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 8
238000013270 controlled release Methods 0.000 claims description 7
JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 6
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims description 4
102000005157 Somatostatin Human genes 0.000 claims description 4
108010056088 Somatostatin Proteins 0.000 claims description 4
229920002253 Tannate Polymers 0.000 claims description 4
150000001413 amino acids Chemical class 0.000 claims description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical group CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
230000002035 prolonged effect Effects 0.000 claims description 4
238000010298 pulverizing process Methods 0.000 claims description 4
238000007873 sieving Methods 0.000 claims description 4
229960000553 somatostatin Drugs 0.000 claims description 4
101000904177 Clupea pallasii Gonadoliberin-1 Proteins 0.000 claims description 3
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims description 3
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims description 3
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
102000055006 Calcitonin Human genes 0.000 claims description 2
108060001064 Calcitonin Proteins 0.000 claims description 2
125000000217 alkyl group Chemical group 0.000 claims description 2
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 2
229960004015 calcitonin Drugs 0.000 claims description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 claims description 2
150000002942 palmitic acid derivatives Chemical class 0.000 claims description 2
-1 GH-RH Chemical compound 0.000 claims 1
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 8
102000004196 processed proteins & peptides Human genes 0.000 description 6
238000001727 in vivo Methods 0.000 description 5
230000006835 compression Effects 0.000 description 4
238000007906 compression Methods 0.000 description 4
239000006185 dispersion Substances 0.000 description 4
239000007943 implant Substances 0.000 description 4
230000001954 sterilising effect Effects 0.000 description 4
229960003604 testosterone Drugs 0.000 description 4
241000700159 Rattus Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
238000003801 milling Methods 0.000 description 3
239000002904 solvent Substances 0.000 description 3
238000004659 sterilization and disinfection Methods 0.000 description 3
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 2
102000038461 Growth Hormone-Releasing Hormone Human genes 0.000 description 2
101710142969 Somatoliberin Proteins 0.000 description 2
108010050144 Triptorelin Pamoate Proteins 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
238000004090 dissolution Methods 0.000 description 2
235000012438 extruded product Nutrition 0.000 description 2
239000008187 granular material Substances 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
229920000642 polymer Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
BIIBYWQGRFWQKM-JVVROLKMSA-N (2S)-N-[4-(cyclopropylamino)-3,4-dioxo-1-[(3S)-2-oxopyrrolidin-3-yl]butan-2-yl]-2-[[(E)-3-(2,4-dichlorophenyl)prop-2-enoyl]amino]-4,4-dimethylpentanamide Chemical compound CC(C)(C)C[C@@H](C(NC(C[C@H](CCN1)C1=O)C(C(NC1CC1)=O)=O)=O)NC(/C=C/C(C=CC(Cl)=C1)=C1Cl)=O BIIBYWQGRFWQKM-JVVROLKMSA-N 0.000 description 1
KGLGUDHEKBYBDR-UHFFFAOYSA-N 6-amino-N-[1-[[1-[[1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-sulfanylpropan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-2-[[2-[[2-[[2-[(2-amino-3-phenylpropanoyl)amino]-3-sulfanylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]hexanamide Chemical compound C=1NC2=CC=CC=C2C=1CC(C(N)=O)NC(=O)C(CS)NC(=O)C(C(C)C)NC(=O)C(CCCCN)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(NC(=O)C(CS)NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=C(O)C=C1 KGLGUDHEKBYBDR-UHFFFAOYSA-N 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
239000012888 bovine serum Substances 0.000 description 1
238000010924 continuous production Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
238000007580 dry-mixing Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000000463 material Substances 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
108700029852 vapreotide Proteins 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/23—Calcitonins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/31—Somatostatins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Zoology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Dermatology (AREA)
Reproductive Health (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Compositions Of Macromolecular Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL9512090A 1989-07-28 1990-07-18 Preparation of sustained release pharmaceutical compositions comprising peptide salts, in the form of microparticles IL95120A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH2829/89A CH679207A5 (sv)	1989-07-28	1989-07-28

Publications (2)

Publication Number	Publication Date
IL95120A0 IL95120A0 (en)	1991-06-10
IL95120A true IL95120A (en)	1994-10-07

Family

ID=4242536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9512090A IL95120A (en)	1989-07-28	1990-07-18	Preparation of sustained release pharmaceutical compositions comprising peptide salts, in the form of microparticles

Country Status (23)

Country	Link
US (1)	US5134122A (sv)
JP (1)	JPH0662427B2 (sv)
AT (1)	AT397197B (sv)
AU (1)	AU619996B2 (sv)
BE (1)	BE1003093A3 (sv)
CA (1)	CA2021767C (sv)
CH (1)	CH679207A5 (sv)
DE (1)	DE4023134C2 (sv)
DK (1)	DK175495B1 (sv)
ES (1)	ES2020890A6 (sv)
FI (1)	FI97688C (sv)
FR (1)	FR2650182B1 (sv)
GB (1)	GB2234169B (sv)
GR (1)	GR1001215B (sv)
IE (1)	IE65397B1 (sv)
IL (1)	IL95120A (sv)
IT (1)	IT1243357B (sv)
LU (1)	LU87772A1 (sv)
NL (1)	NL194858C (sv)
NO (1)	NO300304B1 (sv)
PT (1)	PT94842B (sv)
SE (1)	SE504279C2 (sv)
ZA (1)	ZA905654B (sv)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5538739A (en) *	1989-07-07	1996-07-23	Sandoz Ltd.	Sustained release formulations of water soluble peptides
PH30995A (en) *	1989-07-07	1997-12-23	Novartis Inc	Sustained release formulations of water soluble peptides.
CH681425A5 (sv) *	1990-11-14	1993-03-31	Debio Rech Pharma Sa
DK0528978T3 (da) *	1990-05-16	2003-02-17	Southern Res Inst	Mikrokapsler til reguleret afgivelse og deres anvendelse i stimulering af nervefibervækst
US6517859B1 (en)	1990-05-16	2003-02-11	Southern Research Institute	Microcapsules for administration of neuroactive agents
CH683149A5 (fr) *	1991-07-22	1994-01-31	Debio Rech Pharma Sa	Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US5470582A (en) *	1992-02-07	1995-11-28	Syntex (U.S.A.) Inc.	Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
US6013853A (en) *	1992-02-14	2000-01-11	The University Of Texas System	Continuous release polymeric implant carrier
US5876452A (en) *	1992-02-14	1999-03-02	Board Of Regents, University Of Texas System	Biodegradable implant
GB9211268D0 (en) *	1992-05-28	1992-07-15	Ici Plc	Salts of basic peptides with carboxyterminated polyesters
US5456917A (en) *	1993-04-12	1995-10-10	Cambridge Scientific, Inc.	Method for making a bioerodible material for the sustained release of a medicament and the material made from the method
CA2178592C (en) *	1993-12-09	2009-07-28	Jurgen Engel	Long-acting injection suspensions and a process for their preparation
DE4342092B4 (de) *	1993-12-09	2007-01-11	Zentaris Gmbh	Langwirkende Injektionssuspension und Verfahren zur Herstellung
US5417982A (en) *	1994-02-17	1995-05-23	Modi; Pankaj	Controlled release of drugs or hormones in biodegradable polymer microspheres
US5569468A (en) *	1994-02-17	1996-10-29	Modi; Pankaj	Vaccine delivery system for immunization, using biodegradable polymer microspheres
US5430021A (en) *	1994-03-18	1995-07-04	Pharmavene, Inc.	Hydrophobic drug delivery systems
US5595760A (en) *	1994-09-02	1997-01-21	Delab	Sustained release of peptides from pharmaceutical compositions
FR2748205A1 (fr)	1996-05-06	1997-11-07	Debio Rech Pharma Sa	Compositions pharmaceutiques pour la liberation controlee de principes actifs insolubles
US5945128A (en) *	1996-09-04	1999-08-31	Romano Deghenghi	Process to manufacture implants containing bioactive peptides
CA2267930A1 (en) *	1996-10-09	1998-04-16	Nobuyuki Takechi	A method for producing a microparticle
AU5678398A (en) *	1997-01-29	1998-08-18	Takeda Chemical Industries Ltd.	Sustained-release microspheres, their production and use
US6071982A (en) *	1997-04-18	2000-06-06	Cambridge Scientific, Inc.	Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
EP1028746B1 (en)	1997-11-07	2003-02-26	Chiron Corporation	Method for producing igf-i sustained-release formulations
IT1304152B1 (it) *	1998-12-10	2001-03-08	Mediolanum Farmaceutici Srl	Composizioni comprendenti un peptide ed acido polilattico-glicolicoatte alla preparazione di impianti sottocutanei aventi un prolungato
US6455526B1 (en)	1998-12-16	2002-09-24	Aventis Pharmaceuticals, Inc.	Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
TR200101759T2 (tr) *	1998-12-16	2001-12-21	Aventis Pharmaceuticals Inc.	Biyolojik olarak çözünebilir polimer kapsülü içindeki serotonin alıcısı antagonisti.
US8206749B1 (en)	1999-02-26	2012-06-26	Novartis Vaccines And Diagnostics, Inc.	Microemulsions with adsorbed macromolecules and microparticles
US7713739B1 (en)	2000-11-17	2010-05-11	Novartis Vaccines And Diagnostics, Inc.	Microparticle-based transfection and activation of dendritic cells
ES2169980B1 (es)	1999-12-17	2003-11-01	Lipotec Sa	Microcapsulas para la liberacion prolongada de farmacos.
US6362308B1 (en) *	2000-08-10	2002-03-26	Alkermes Controlled Therapeutics Inc. Ii	Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
MXPA03009727A (es) *	2001-04-26	2004-01-29	Control Delivery Sys Inc	SISTEMA DE SUMINISTRO DE FaRMACOS DE LIBERACIoN PROLONGADA QUE CONTIENE COFARMACOS.
US20040022853A1 (en) *	2001-04-26	2004-02-05	Control Delivery Systems, Inc.	Polymer-based, sustained release drug delivery system
SK14182003A3 (sk) *	2001-05-23	2004-05-04	Hexal Ag	Homogenizát pre implantáty a mikročastice
JP2004535431A (ja)	2001-06-22	2004-11-25	サザンバイオシステムズ，インコーポレイテッド	ゼロ次長期放出同軸インプラント
IN2014DN10834A (sv) *	2001-09-17	2015-09-04	Psivida Inc
KR101139112B1 (ko) *	2002-06-25	2012-04-30	다케다 야쿠힌 고교 가부시키가이샤	서방성 조성물의 제조 방법
SG168407A1 (en)	2003-01-28	2011-02-28	Ironwood Pharmaceuticals Inc	Methods and compositions for the treatment of gastrointestinal disorders
US7772188B2 (en)	2003-01-28	2010-08-10	Ironwood Pharmaceuticals, Inc.	Methods and compositions for the treatment of gastrointestinal disorders
GB0304726D0 (en) *	2003-03-01	2003-04-02	Ardana Bioscience Ltd	New Process
CA2523830A1 (en) *	2003-04-30	2004-11-11	Debiopharm S.A.	Methods and compositions using gonadotropin hormone releasing hormone
WO2005020933A2 (en) *	2003-09-02	2005-03-10	University Of South Florida	Nanoparticles for drug-delivery
CA2544678C (en)	2003-11-05	2013-12-31	Sunesis Pharmaceuticals, Inc.	Modulators of cellular adhesion
WO2005063276A1 (en) *	2003-12-23	2005-07-14	Debiopharm S.A.	Methods and compositions using gonadotropin hormone releasing hormone
FR2865938B1 (fr) *	2004-02-05	2006-06-02	Sod Conseils Rech Applic	Formulation retard solide comprenant de l'acetate de triptoreline
AU2005325213B2 (en)	2004-08-04	2010-10-07	Evonik Corporation	Methods for manufacturing delivery devices and devices thereof
AU2005279772A1 (en)	2004-08-30	2006-03-09	Spineovations, Inc.	Method of treating spinal internal disk derangement
EP1674082A1 (de) *	2004-12-22	2006-06-28	Zentaris GmbH	Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
PL2444079T3 (pl) *	2005-05-17	2017-07-31	Sarcode Bioscience Inc.	Kompozycje i sposoby leczenia chorób oczu
KR100722607B1 (ko) *	2006-05-11	2007-05-28	주식회사 펩트론	분산성 및 주사 투여능이 향상된 서방성 미립구의 제조방법
US20100120694A1 (en)	2008-06-04	2010-05-13	Synergy Pharmaceuticals, Inc.	Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
US8969514B2 (en)	2007-06-04	2015-03-03	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2527360B1 (en)	2007-06-04	2015-10-28	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8034782B2 (en)	2008-07-16	2011-10-11	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
LT2500014T (lt) *	2007-06-06	2019-01-25	Debiopharm International Sa	Lėto atpalaidavimo mikrodalelių farmacinė kompozicija
CA2702984C (en)	2007-10-19	2017-04-11	Sarcode Corporation	Compositions and methods for treatment of diabetic retinopathy
ES2718612T3 (es)	2007-12-20	2019-07-03	Evonik Corp	Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
US20100010549A1 (en) *	2008-03-05	2010-01-14	Neville Alleyne	device and method of minimally invasive extracapsular ligamentous augmentation for canine stifle ligament injuries
US8469961B2 (en) *	2008-03-05	2013-06-25	Neville Alleyne	Methods and compositions for minimally invasive capsular augmentation of canine coxofemoral joints
CN102065893A (zh) *	2008-04-15	2011-05-18	萨可德公司	Lfa-1拮抗剂向胃肠***的递送
US8080562B2 (en)	2008-04-15	2011-12-20	Sarcode Bioscience Inc.	Crystalline pharmaceutical and methods of preparation and use thereof
JP2012524779A (ja) *	2009-04-23	2012-10-18	サステインドナノシステムズリミテッドライアビリティカンパニー	制御放出分配デバイス
WO2011050175A1 (en)	2009-10-21	2011-04-28	Sarcode Corporation	Crystalline pharmaceutical and methods of preparation and use thereof
US9616097B2 (en)	2010-09-15	2017-04-11	Synergy Pharmaceuticals, Inc.	Formulations of guanylate cyclase C agonists and methods of use
KR101411349B1 (ko)	2010-12-24	2014-06-25	주식회사 삼양바이오팜	생리활성 펩타이드를 포함하는 마이크로입자 및 그의 제조방법, 및 그를 포함하는 약제학적 조성물
JP6092849B2 (ja)	2011-05-04	2017-03-08	バランスセラピューティックス, インコーポレイテッドBalance Therapeutics, Inc.	ペンチレンテトラゾール誘導体
EP2630964A1 (en) *	2012-02-22	2013-08-28	Immundiagnostik AG	Method and medicament for treating patients in risk of prediabetes and type-2 diabetes
TWI636799B (zh)	2012-05-14	2018-10-01	日商帝人股份有限公司	滅菌組成物
JP6607780B2 (ja)	2012-07-25	2019-11-20	サルコード・バイオサイエンス・インコーポレイテッド	Ｌｆａ−１阻害剤およびその多形
EP3718557A3 (en)	2013-02-25	2020-10-21	Bausch Health Ireland Limited	Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing
CA2905435A1 (en)	2013-03-15	2014-09-25	Synergy Pharmaceuticals Inc.	Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en)	2013-03-15	2016-01-20	Synergy Pharmaceuticals Inc.	Agonists of guanylate cyclase and their uses
MX2016004444A (es) *	2013-10-08	2016-11-10	Ferring Bv	Microparticulas que comprenden gnrh hechas mediante pgss.
CA2926691A1 (en)	2013-10-10	2015-04-16	Synergy Pharmaceuticals, Inc.	Agonists of guanylate cyclase useful for the treatment of opioid induced dysfunctions
AU2016206507B2 (en)	2015-01-16	2020-12-17	Spineovations, Inc.	Method of treating spinal disk
CA3009814A1 (en)	2016-01-11	2017-07-20	Synergy Pharmaceuticals, Inc.	Formulations and methods for treating ulcerative colitis
JP7493796B2 (ja)	2017-07-11	2024-06-03	サステインドナノシステムズエルエルシー	超圧縮医薬製剤
CN111032054A (zh)	2017-07-11	2020-04-17	持续纳米***有限责任公司	超压缩聚合物剂型的辐射灭菌
WO2019066649A1 (en)	2017-09-26	2019-04-04	Nanomi B.V.	PROCESS FOR THE PREPARATION OF MICROPARTICLES BY A DOUBLE EMULSION TECHNIQUE

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3976071A (en) *	1974-01-07	1976-08-24	Dynatech Corporation	Methods of improving control of release rates and products useful in same
US3978203A (en) *	1974-07-12	1976-08-31	Dynatech Corporation	Sustained release of pharmaceuticals from polyester matrices
US4107288A (en) *	1974-09-18	1978-08-15	Pharmaceutical Society Of Victoria	Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US4010125A (en) *	1975-06-12	1977-03-01	Schally Andrew Victor	[D-Trp6 ]-LH-RH and intermediates therefor
US4622244A (en) *	1979-09-04	1986-11-11	The Washington University	Process for preparation of microcapsules
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
PH19942A (en) *	1980-11-18	1986-08-14	Sintex Inc	Microencapsulation of water soluble polypeptides
US4349530A (en) *	1980-12-11	1982-09-14	The Ohio State University	Implants, microbeads, microcapsules, preparation thereof and method of administering a biologically-active substance to an animal
US4483807A (en) *	1981-01-27	1984-11-20	Japan Atomic Energy Research Institute	Process for producing a slow release composite
IE52535B1 (en) *	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
CH661206A5 (fr) *	1983-09-23	1987-07-15	Debiopharm Sa	Procede pour la preparation d'un medicament destine au traitement de maladies hormonodependantes.
JPS60181029A (ja) *	1984-02-29	1985-09-14	Toyo Jozo Co Ltd	徐放性製剤の製法
US4666704A (en) *	1985-05-24	1987-05-19	International Minerals & Chemical Corp.	Controlled release delivery system for macromolecules
IL79134A (en) *	1985-07-29	1991-06-10	American Cyanamid Co	Continuous release peptide implants for parenteral administration
US4962091A (en) *	1986-05-23	1990-10-09	Syntex (U.S.A.) Inc.	Controlled release of macromolecular polypeptides
JPS63218632A (ja) *	1987-03-06	1988-09-12	Japan Atom Energy Res Inst	ホルモンに徐放性機能を付与した生体分解型コポリ（グルコ−ル酸／ｌ−乳酸）複合体の製造方法
US4897268A (en) *	1987-08-03	1990-01-30	Southern Research Institute	Drug delivery system and method of making the same
GB2209937B (en) *	1987-09-21	1991-07-03	Depiopharm S A	Water insoluble polypeptides
DE3734223A1 (de) *	1987-10-09	1989-04-20	Boehringer Ingelheim Kg	Implantierbares, biologisch abbaubares wirkstofffreigabesystem

1989
- 1989-07-28 CH CH2829/89A patent/CH679207A5/fr not_active IP Right Cessation
1990
- 1990-07-16 IE IE259290A patent/IE65397B1/en not_active IP Right Cessation
- 1990-07-17 GB GB9015722A patent/GB2234169B/en not_active Expired - Lifetime
- 1990-07-18 IL IL9512090A patent/IL95120A/en not_active IP Right Cessation
- 1990-07-18 BE BE9000729A patent/BE1003093A3/fr not_active IP Right Cessation
- 1990-07-18 ZA ZA905654A patent/ZA905654B/xx unknown
- 1990-07-18 AU AU59103/90A patent/AU619996B2/en not_active Expired
- 1990-07-19 NL NL9001646A patent/NL194858C/nl not_active IP Right Cessation
- 1990-07-19 FI FI903643A patent/FI97688C/sv active IP Right Grant
- 1990-07-20 US US07/555,973 patent/US5134122A/en not_active Expired - Lifetime
- 1990-07-20 FR FR909009333A patent/FR2650182B1/fr not_active Expired - Lifetime
- 1990-07-20 DE DE4023134A patent/DE4023134C2/de not_active Expired - Lifetime
- 1990-07-23 NO NO903264A patent/NO300304B1/no not_active IP Right Cessation
- 1990-07-23 AT AT0154590A patent/AT397197B/de not_active IP Right Cessation
- 1990-07-23 CA CA002021767A patent/CA2021767C/en not_active Expired - Lifetime
- 1990-07-23 ES ES9001976A patent/ES2020890A6/es not_active Expired - Fee Related
- 1990-07-23 IT IT02101990A patent/IT1243357B/it active IP Right Grant
- 1990-07-25 GR GR900100568A patent/GR1001215B/el not_active IP Right Cessation
- 1990-07-25 LU LU87772A patent/LU87772A1/fr unknown
- 1990-07-27 PT PT94842A patent/PT94842B/pt not_active IP Right Cessation
- 1990-07-27 JP JP2201063A patent/JPH0662427B2/ja not_active Expired - Lifetime
- 1990-07-27 DK DK199001807A patent/DK175495B1/da not_active IP Right Cessation
- 1990-07-27 SE SE9002522A patent/SE504279C2/sv not_active IP Right Cessation

Also Published As

Publication number	Publication date
ES2020890A6 (es)	1991-10-01
DK175495B1 (da)	2004-11-08
NL194858B (nl)	2003-01-06
PT94842B (pt)	1997-04-30
NO903264L (no)	1991-01-29
SE504279C2 (sv)	1996-12-23
PT94842A (pt)	1991-03-20
GB9015722D0 (en)	1990-09-05
GR1001215B (el)	1993-06-21
DK180790A (da)	1991-01-29
DK180790D0 (da)	1990-07-27
FR2650182A1 (fr)	1991-02-01
IT9021019A1 (it)	1992-01-23
CH679207A5 (sv)	1992-01-15
ZA905654B (en)	1991-05-29
JPH0662427B2 (ja)	1994-08-17
DE4023134C2 (de)	1997-04-17
GB2234169A (en)	1991-01-30
JPH0366625A (ja)	1991-03-22
AT397197B (de)	1994-02-25
AU5910390A (en)	1991-01-31
SE9002522L (sv)	1991-01-29
ATA154590A (de)	1993-07-15
IE902592A1 (en)	1991-02-27
SE9002522D0 (sv)	1990-07-27
CA2021767A1 (en)	1991-01-29
FI97688B (sv)	1996-10-31
NL194858C (nl)	2003-05-06
FI903643A0 (sv)	1990-07-19
IT9021019A0 (it)	1990-07-23
IT1243357B (it)	1994-06-10
FR2650182B1 (fr)	1992-05-15
AU619996B2 (en)	1992-02-06
IL95120A0 (en)	1991-06-10
IE65397B1 (en)	1995-10-18
CA2021767C (en)	1996-10-22
FI97688C (sv)	1997-02-10
US5134122A (en)	1992-07-28
LU87772A1 (fr)	1990-12-11
GB2234169B (en)	1993-02-10
NO903264D0 (no)	1990-07-23
GR900100568A (en)	1991-12-10
DE4023134A1 (de)	1991-01-31
BE1003093A3 (fr)	1991-11-19
NL9001646A (nl)	1991-02-18
NO300304B1 (no)	1997-05-12

Legal Events

Date	Code	Title	Description
1996-10-16	KB	Patent renewed
2005-07-25	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
US5134122A (en)	1992-07-28	Method for preparing a pharmaceutical composition in the form of microparticles
US5225205A (en)	1993-07-06	Pharmaceutical composition in the form of microparticles
US5439688A (en)	1995-08-08	Process for preparing a pharmaceutical composition
CA1228542A (en)	1987-10-27	Lyophilized compositions, preparations and use thereof
AU2003217367B2 (en)	2005-09-08	Polymer-based compositions for sustained release
JP2594560B2 (ja)	1997-03-26	巨大分子ポリペプチドの放出速度調節
AU685784B2 (en)	1998-01-29	Excipient stabilization of polypeptides treated with organic solvents
US5597897A (en)	1997-01-28	Pharmaceutical formulations of osteogenic proteins
US4675189A (en)	1987-06-23	Microencapsulation of water soluble active polypeptides
KR101173144B1 (ko)	2012-08-16	뼈 복원용 조성물 및 이의 제조 및 사용방법
EP0138216B1 (en)	1993-01-07	Sustained-release ifn preparation for parenteral administration
MXPA05010635A (es)	2005-12-12	Formulaciones farmaceuticas liquidas de hormona estimulante de foliculos y hormona luteinizante junto con un surfactante no ionico.
AU2004251456A1 (en)	2005-01-06	Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a PLGA matrix
NZ215730A (en)	1988-03-30	Sustained-release peptide compositions containing proteins as carriers
GB2249725A (en)	1992-05-20	Biodegradable microparticles or implant containing insoluble peptide salts
JPH04217914A (ja)	1992-08-07	徐放性製剤の製造方法
CH685285A5 (fr)	1995-05-31	Procédé de préparation d'une composition pharmaceutique contenant des sels de peptides.